Plain-English translation of NCT05016817 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing cultured allogeneic adult umbilical cord derived mesenchymal stem cells—a type of laboratory-grown cell therapy—to see if it's safe and whether it can help improve lung function in people with idiopathic pulmonary fibrosis (IPF). You would receive a single intravenous infusion of 100 million of these cells. Researchers will monitor you for safety and effectiveness over the next four years with several follow-up visits and tests.
IPF is a serious condition where lung tissue becomes scarred and stiff, making it harder to breathe. Early research suggests that stem cell therapy may be safe and could potentially slow or improve the disease, but this trial is needed to carefully test whether this treatment actually works and is safe for IPF patients.
You likely qualify if…
You likely don't qualify if…
You would have one screening visit within a month before treatment to undergo blood tests and other evaluations. Then you would receive a single intravenous infusion of the stem cells, which takes place as an outpatient procedure. After that, you would return for follow-up visits at 1 month, 6 months, 12 months, 24 months, 36 months, and 48 months to have blood tests, lung function tests, and imaging scans to check your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Antigua and Barbuda
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~20 participants
Started
July 2022
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.